A fundus photo showing intermediate age-related macular degeneration. Credit: National Eye Institute, National Institutes of Health.

Ophthotech has completed patient enrolment in its Phase IIa clinical trial of Zimura (avacincaptad pegol) in combination with Lucentis (ranibizumab) for treating naïve patients with wet age-related macular degeneration (AMD).

AMD is a medical condition that could lead to blurred or no vision in the centre of the visual field.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The dose-ranging, multi-centre trial includes a total of 64 patients.

The trial aims to evaluate safety at different dosages and to identify a potential efficacy signal.

"Data from the trial is expected to be evaluated at month six, while initial top-line data are scheduled to be provided before the end of this year."

Data from the trial is expected to be evaluated at month six, while initial top-line data are scheduled to be provided before the end of this year.

Ophthotech chief medical officer Kourous Rezaei said: “Following the completion of this trial, clinical data will be analysed to assess whether to proceed to a randomised, sham controlled clinical trial of Zimura combination therapy in wet AMD.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Zimura (avacincaptad pegol) was developed by Ophthotech as a complement factor C5 inhibitor for treating patients with wet AMD.

Apart from the Phase IIa, Zimura is currently being investigated as monotherapy in a Phase IIb clinical trial for patients with geographic atrophy secondary to dry AMD and in a Phase IIb clinical trial for the prevention of autosomal recessive Stargardt disease (STGD1).

Additionally, Zimura is being analysed as combination therapy with Eylea (aflibercept), an anti-VEGF agent, in patients with idiopathic polypoidal choroidal vasculopathy (IPCV).

Lucentis (ranibizumab) is an anti-vascular endothelial growth factor (anti-VEGF) agent.